KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Current Deferred Revenue (2016 - 2026)

Ionis Pharmaceuticals (IONS) has disclosed Current Deferred Revenue for 18 consecutive years, with $69.2 million as the latest value for Q1 2026.

  • For Q1 2026, Current Deferred Revenue rose 1509.28% year-over-year to $69.2 million; the TTM value through Mar 2026 reached $69.2 million, up 1509.28%, while the annual FY2025 figure was $73.8 million, 6.62% down from the prior year.
  • Current Deferred Revenue hit $69.2 million in Q1 2026 for Ionis Pharmaceuticals, down from $73.8 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $204.8 million in Q3 2023 and bottomed at $4.3 million in Q1 2025.
  • Average Current Deferred Revenue over 5 years is $94.1 million, with a median of $91.4 million recorded in 2022.
  • Year-over-year, Current Deferred Revenue crashed 96.7% in 2025 and then soared 1509.28% in 2026.
  • Ionis Pharmaceuticals' Current Deferred Revenue stood at $90.6 million in 2022, then skyrocketed by 66.85% to $151.1 million in 2023, then plummeted by 47.73% to $79.0 million in 2024, then decreased by 6.62% to $73.8 million in 2025, then decreased by 6.18% to $69.2 million in 2026.
  • According to Business Quant data, Current Deferred Revenue over the past three periods came in at $69.2 million, $73.8 million, and $77.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.